Pharmacokinetics of Teicoplanin in a Patient with Coronavirus Disease 2019 Receiving Veno-venous Extracorporeal Membrane Oxygenation

Hirayu Nobuhisa; Nakamura Atsuo; Morita Toshio; Takasu Osamu

doi:10.2478/jccm-2022-0021

The Journal of Critical Care Medicine (Nov 2022)

Pharmacokinetics of Teicoplanin in a Patient with Coronavirus Disease 2019 Receiving Veno-venous Extracorporeal Membrane Oxygenation

Hirayu Nobuhisa,
Nakamura Atsuo,
Morita Toshio,
Takasu Osamu

Affiliations

Hirayu Nobuhisa: Department of Emergency and Critical Care Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan
Nakamura Atsuo: Department of Emergency and Critical Care Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan
Morita Toshio: Department of Emergency and Critical Care Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan
Takasu Osamu: Department of Emergency and Critical Care Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan

DOI: https://doi.org/10.2478/jccm-2022-0021
Journal volume & issue: Vol. 8, no. 4
pp. 288 – 291

Abstract

Read online

Patients with severe coronavirus disease 2019 (COVID-19) receiving ventilation or pulmonary support via veno-venous extracorporeal membrane oxygenation (VV-ECMO) can be infected with drug-resistant bacteria. When introducing VV-ECMO, the changes in serum antibiotic concentration should be considered due to an increased volume of distribution (Vd). However, no pharmacokinetic study has assessed teicoplanin (TEIC) treatment in patients with COVID-19 receiving VV-ECMO.

Published in The Journal of Critical Care Medicine

ISSN: 2393-1809 (Print); 2393-1817 (Online)
Publisher: Sciendo
Country of publisher: Poland
LCC subjects: Medicine: Internal medicine: Medical emergencies. Critical care. Intensive care. First aid
Website: https://sciendo.com/journal/jccm?tab=aims-scope

About the journal

Abstract

Keywords